Prosecution Insights
Last updated: April 19, 2026
Application No. 18/393,497

EMITTERS BASED ON OCTAHEDRAL METAL COMPLEXES

Non-Final OA §112
Filed
Dec 21, 2023
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Arizona Board of Regents
OA Round
5 (Non-Final)
81%
Grant Probability
Favorable
5-6
OA Rounds
2y 3m
To Grant
65%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
1407 granted / 1741 resolved
+20.8% vs TC avg
Minimal -16% lift
Without
With
+-16.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
54 currently pending
Career history
1795
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
15.2%
-24.8% vs TC avg
§102
21.0%
-19.0% vs TC avg
§112
42.6%
+2.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1741 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . According to paper filed on Nov. 20, 2025, the applicants have filed RCE. The applicants have also canceled claims 34-35, amended claims 16, 21, 23, 24 and 31 and furthermore, have added a new claim 36. Claims 16-24, 26-33 and 36 are pending in the application. Claims 20 and 26 remain withdrawn as being directed to non-elected subject matter. Response to Arguments Applicant's arguments filed on Nov. 20, 2025 have been fully considered but they are not persuasive regarding written description rejection and Improper Markush Group rejection. The applicants have amended claims to overcome indefiniteness rejection. Regarding written description rejection, the applicants argue on page 84 that the values of variables L1 and L3-L6 are amended to overcome this rejection and further point out exemplary compounds in paragraph 00127 of the specification. The examiner does not agree with these arguments. In the exemplary compounds in paragraph 00127, there is not even a single metal complex where variables L1 and L3-L6 represent either 5-membered hereroaryl ring or 6-membered heteroaryl ring containing only one O or S atom as heteroatom, 5- or 6-membered heteroaryl rings containing 2-3 O or S atoms as heteroatoms, 6-memberd heteroaryl ring containing N and O or S atoms, 5-membered heteroaryl rings containing 1 N, 1 O and 1 S as heteroatoms and 5-membered heteroaryl rings containing one N and 2 O or 2S atoms as heteroatoms. In regard to Improper Markush group rejection, the applicants argue on pages 85-86 that the values of variables L1-L6 are amended to overcome this rejection. The examiner does not agree with these arguments. As stated clearly in the previous office action, specific values of variables L1-L6, V1-V6, metal, X, Y and Z are critical for the common core of these metal complexes. As stated earlier, prior art reference was found against specific species. Therefore, search will not be extended to any additional species. Claims must be amended to read upon the elected species. Conclusion The written description rejection of claims 16-19, 21-24, 27-33 and 36 under 35 U.S.C. 112, 1st paragraph is maintained. The Improper Markush Group rejection of claims 16-19, 21-24, 27-33 and 36 is maintained. NEW GROUNDS OF REJECTION Claim Rejections - 35 USC § 112 7. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 16-19, 21-24, 27-33 and 36 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In independent claim 16 and 21, the values of variables L1-L6 are defined as aryl or 5- to 6-membered substituted or unsubstituted heteroaryl rings. However, the claims also mention that atleast one of F1-F6 must be present. Therefore, it is not clear how one of F1-F6 can be present when all variables L1-L6 are unsubstituted. Claim 23 recites the limitation "bicyclic aryl and 9-10 membered heteroaryl rings for the values of variables L1-L6" in claim 16. There is insufficient antecedent basis for this limitation in the claim. Claim 24 recites the limitation "bicyclic aryl and 9-10 membered heteroaryl rings for the values of variables L1-L6" in claim 16. There is insufficient antecedent basis for this limitation in the claim. Claim 27 recites the limitation "P-containing heteroaryl ring for the values of variables L1 and L3-L6 (see pages 18, 19, 43, 44 and 68)" in claim 16. There is insufficient antecedent basis for this limitation in the claim. Claim 27 recites the limitation "bicyclic 9-10 membered heteroaryl rings for the values of variables L1 and L3-L6 (see pages 31, 33-35, 38-40, 50, 53, 56, 58-60, 64-65, 73-74, 76 and 78-79)" in claim 16. There is insufficient antecedent basis for this limitation in the claim. Claim 27 recites the limitation "other values besides aryl or heteroaryl rings for the values of variables L3-L6 (see pages 37, 38 and 66)" in claim 16. There is insufficient antecedent basis for this limitation in the claim. Claim 36 recites the limitation "bicyclic 9-10 membered heteroaryl ring for the values of variables L1 and L3-L6" in claim 16. There is insufficient antecedent basis for this limitation in the claim. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Dec 21, 2023
Application Filed
Sep 30, 2024
Non-Final Rejection — §112
Dec 27, 2024
Response Filed
Jan 13, 2025
Final Rejection — §112
Apr 15, 2025
Response after Non-Final Action
Apr 22, 2025
Request for Continued Examination
Apr 25, 2025
Response after Non-Final Action
Apr 30, 2025
Non-Final Rejection — §112
Aug 05, 2025
Response Filed
Aug 18, 2025
Final Rejection — §112
Nov 20, 2025
Request for Continued Examination
Nov 24, 2025
Response after Non-Final Action
Dec 15, 2025
Non-Final Rejection — §112
Feb 04, 2026
Interview Requested
Feb 10, 2026
Applicant Interview (Telephonic)
Feb 10, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594251
BENZALKONIUM CHLORIDE FORUSE IN TREATING CONJUNCTIVITIS AND/OR COVID-19
2y 5m to grant Granted Apr 07, 2026
Patent 12583829
SALT OF BENZOTHIAZOLE COMPOUND, AND CRYSTAL FORM AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12581852
COMPOUND, LUMINESCENT MATERIAL, DELAYED FLUORESCENT MATERIAL, AND ORGANIC OPTICAL DEVICE
2y 5m to grant Granted Mar 17, 2026
Patent 12569479
BUPROPION AS A MODULATOR OF DRUG ACTIVITY
2y 5m to grant Granted Mar 10, 2026
Patent 12564586
KAPPA OPIOD RECEPTOR ANTAGONISTS FOR TREATING PAIN-RELATED SLEEP DISORDERS
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
81%
Grant Probability
65%
With Interview (-16.0%)
2y 3m
Median Time to Grant
High
PTA Risk
Based on 1741 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month